Burden of all-cause and organism-specific parapneumonic empyema hospitalization rates prior to the SARS-CoV-2 pandemic in the United States.

Authors:
Wiese AD; Grijalva CG.

Journal:
Respir Med

Publication Year: 2022

DOI:
10.1016/j.rmed.2022.107111

PMCID:
PMC9803378

PMID:
36592639

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respir Med

Abbreviation: Respir Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patien…
Keur N; Saridaki M; Ricaño-Ponce I and 3 more (2023) - Transparency Score: 4/6
Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A pos…
Datta B; Prakash AK; Yaddanapudi K and 7 more (2023) - Transparency Score: 3/6
Lung ultrasound as a tool for monitoring the interstitial changes in recently hospitalised patients…
Loke TK; Earl N; Begbey ACH and 7 more (2023) - Transparency Score: 3/6
Multiple manifestations of uncontrolled asthma increase the risk of severe COVID-19.
Selberg S; Karlsson Sundbaum J; Konradsen JR and 4 more (2023) - Transparency Score: 3/6
Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and ou…
Ragnoli B; Cena T; Radaeli A and 5 more (2023) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of competing interest C.G.G. reports consulting fees from 10.13039/100004319Pfizer and 10.13039/100004334Merck, and received research support from Sanofi-Pasteur, and the Campbell Alliance/Syneos Health. A.D.W. reports consulting fees from the Tennessee 10.13039/100004856Department of Health."

Evidence found in paper:

"Funding ADW reported support from the 10.13039/100000026National Institute on Drug Abuse (K01DA051683). CGG reported support from the National Institute of Allergies and Infectious Diseases (K24 AI148459); other grants or contracts from: 10.13039/100000060NIAID, 10.13039/100000030CDC, 10.13039/100000038FDA, 10.13039/100016655Campbell Alliance/Syneos Health; consulting fees: 10.13039/100004334Merck."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025